Acadia Pharmaceuticals (ACAD) Other Operating Expenses (2015 - 2026)

Acadia Pharmaceuticals' Other Operating Expenses history runs 12 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• On a quarterly basis, Other Operating Expenses rose 21.57% year-over-year to $24.8 million in Q1 2026; TTM through Mar 2026 was $93.4 million, a 238.92% increase from a year earlier, with the FY2024 full-year figure at $146.5 million, changed N/A from the prior year.
• Other Operating Expenses fell to $24.8 million in Q1 2026 per ACAD's latest filing, from $26.2 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $26.2 million in Q4 2025 and bottomed at -$124.7 million in Q4 2024.
• The 5-year median for Other Operating Expenses is $17.9 million (2023), against an average of $5.9 million.
• Biggest YoY gain for Other Operating Expenses was 1276.78% in 2024; the steepest drop was 797.07% in 2024.
• Year by year, Other Operating Expenses stood at $2.4 million in 2022, then jumped by 641.44% to $17.9 million in 2023, then sank by 797.07% to -$124.7 million in 2024, then soared by 121.03% to $26.2 million in 2025, then declined by 5.47% to $24.8 million in 2026.
• Per Business Quant, the three latest ACAD Other Operating Expenses figures stand at $24.8 million (Q1 2026), $26.2 million (Q4 2025), and $21.6 million (Q3 2025).